Mary Markiewicz, PhD, is an Associate Professor in the Department of Microbiology, Molecular Genetics & Immunology at the University of Kansas Medical Center, and a member of the University of Kansas Cancer Center. She is a cellular immunologist with a strong interest in both tumor immunology and type 1 diabetes research. Dr. Markiewicz received her PhD in Immunology from the University of Chicago, where she performed tumor immunology studies. Dr. Markiewicz then moved to the Department of Pathology and Immunology at the Washington University School of Medicine in St. Louis and began her studies on the NKG2D immune receptor with a Postdoctoral Fellowship from the American Cancer Society. After completing her postdoctoral training, she became a Research Assistant Professor in the Department of Pathology and Immunology at Washington University School of Medicine. During this time, propelled by funding from a Junior Faculty Award from the American Diabetes Association, she began her studies investigating the role of NKG2D in autoimmune diabetes. With funding from the Molecular Regulation of Cell Development and Differentiation COBRE, Dr. Markiewicz joined the KUMC faculty in as an Assistant Professor in 2014. Dr. Markiewicz continues both her type 1 diabetes studies, which has been funded in part by the Department of Defense, The Beatson Foundation, and The University of Kansas Diabetes Institute, and studies into the role of NKG2D signaling in cancer immunotherapy strategies, which have been funded by the V Foundation and the University of Kansas Cancer Center. Dr. Markiewicz has also been the Scientific Director of the University of Kansas Flow Cytometry Core since 2017.